New Investigational Drug for CF Patients with NTM Infection

Trial Objective

This study will determine if a new investigational drug helps treat ongoing nontuberculous mycobacterial (NTM) infection in adults with cystic fibrosis. The medication, Molgramostim Nebulized Solution, is not an antibiotic, but is designed to stimulate an immune response to better fight infection. Participants will nebulize the drug once a day after their full morning routine. Everyone in the trial will get the active drug.

New Investigational Drug for CF Patients with NTM Infection

Enrollment

This trial is active and currently recruiting.

How to Participate

For more information, contact Alexandria Leonhardt at 303.398.1453 or complete the form below.

Who Can Participate

Adults who are diagnosed with cystic fibrosis and have ongoing mycobacterial infection.


Estimated Time Commitment

Study involvement will last for about 18 months.

Participants will nebulize the drug for 48 weeks. There are 19 visits that take 3-4 hours each.

Trial Location

National Jewish Main Campus, Denver, CO

Compensation

Provided

Trial Sponsors

SAVARA

Age

18+


Gender

Any Gender

Principal Investigators

Co-Investigators


Request More Information

*
*
*
*